Zobrazeno 1 - 10
of 36
pro vyhledávání: '"Vikas S. Sridhar"'
Autor:
Kumar Sharma, Guanshi Zhang, Jens Hansen, Petter Bjornstad, Hak Joo Lee, Rajasree Menon, Leila Hejazi, Jian-Jun Liu, Anthony Franzone, Helen C. Looker, Byeong Yeob Choi, Roman Fernandez, Manjeri A. Venkatachalam, Luxcia Kugathasan, Vikas S. Sridhar, Loki Natarajan, Jing Zhang, Varun S. Sharma, Brian Kwan, Sushrut S. Waikar, Jonathan Himmelfarb, Katherine R. Tuttle, Bryan Kestenbaum, Tobias Fuhrer, Harold I. Feldman, Ian H. de Boer, Fabio C. Tucci, John Sedor, Hiddo Lambers Heerspink, Jennifer Schaub, Edgar A. Otto, Jeffrey B. Hodgin, Matthias Kretzler, Christopher R. Anderton, Theodore Alexandrov, David Cherney, Su Chi Lim, Robert G. Nelson, Jonathan Gelfond, Ravi Iyengar, for the Kidney Precision Medicine Project
Publikováno v:
The Journal of Clinical Investigation, Vol 133, Iss 20 (2023)
Diabetic kidney disease (DKD) can lead to end-stage kidney disease (ESKD) and mortality; however, few mechanistic biomarkers are available for high-risk patients, especially those without macroalbuminuria. Urine from participants with diabetes from t
Externí odkaz:
https://doaj.org/article/15a3cc7202a34114a72f51162fa19310
Publikováno v:
Endocrinology and Metabolism, Vol 36, Iss 2, Pp 256-269 (2021)
Over the last 5 years there have been many new developments in the management of diabetic kidney disease. Glucagon-like peptide-1 receptor agonists (GLP-1 RA) and sodium-glucose cotransporter-2 (SGLT2) inhibitors were initially used for glycemic cont
Externí odkaz:
https://doaj.org/article/dcdef2be7f3f470bbc1be5e22dbefee0
Publikováno v:
Brazilian Journal of Nephrology, Vol 42, Iss 4, Pp 467-477 (2020)
ABSTRACT Sodium glucose cotransporter-2 (SGLT2) inhibitors and glucagon-like peptide-1 receptor agonists (GLP-1RA) were initially approved to improve glycemic control in the treatment of type 2 diabetes. Clinical trials have also demonstrated benefic
Externí odkaz:
https://doaj.org/article/202829ca93bc469f842ee2434594b810
Publikováno v:
Canadian Journal of Kidney Health and Disease, Vol 8 (2021)
Background: Nephrectomy is the mainstay of treatment for many kidney cancers, but has been correlated with increased incidence of acute kidney injury (AKI) and chronic kidney disease (CKD). Recently, sodium-glucose cotransporter-2 (SGLT2) inhibition
Externí odkaz:
https://doaj.org/article/5df261a382d845ebb54c6afa425308e5
Autor:
Vikas S Sridhar, Donald J Fraser
Publikováno v:
Peritoneal Dialysis International: Journal of the International Society for Peritoneal Dialysis. 43:115-118
Publikováno v:
Annual Review of Medicine. 74:369-384
Sodium-glucose cotransporter-2 inhibitors (SGLT2 inhibitors) were originally developed as antidiabetic agents, with cardiovascular (CV) outcome trials demonstrating improved CV outcomes in patients with type 2 diabetes mellitus (T2D). Secondary analy
Autor:
Vikas S. Sridhar, Brendon L. Neuen, Robert A. Fletcher, April Slee, Fernando G. Ang, Wally Rapattoni, Clare Arnott, David Z. Cherney, Vlado Perkovic, David C. Wheeler, Adeera Levin
Publikováno v:
Diabetes, Obesity and Metabolism.
Autor:
Vikas S. Sridhar, Hiddo J.L. Heerspink, Michael J. Davies, Phillip Banks, Manon Girard, Satish K. Garg, David Z.I. Cherney
Publikováno v:
Diabetes Care.
Publikováno v:
Current Diabetes Reports. 22:317-332
Autor:
Elisabeth B Stougaard, Peter L Kristensen, Urd Kielgast, Henrik U Andersen, Yasmin Hamid, Peter H Gæde, Esben Søndergaard, Gry H Dørflinger, Karen K Fjeldborg, Klavs W Hansen, Henrik H Thomsen, Thuraya M.J. Al-Imar, Michael Røder, Vikas S Sridhar, David Cherney, Peter Rossing, Frederik Persson
Publikováno v:
Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5, pp. 14791641221130043 . https://doi.org/10.1177/14791641221130043
Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5 . https://doi.org/10.1177/14791641221130043
Stougaard, E B, Kristensen, P L, Kielgast, U, Andersen, H U, Hamid, Y, Gæde, P H, Søndergaard, E, Dørflinger, G H, Fjeldborg, K K, Hansen, K W, Thomsen, H H, Al-Imar, T M J, Røder, M, Sridhar, V S, Cherney, D, Rossing, P & Persson, F 2022, ' Real life evaluation of sodium-glucose cotransporter 2 inhibition in type 1 diabetes and the risk of diabetic ketoacidosis ', Diabetes & vascular disease research, vol. 19, no. 5 . https://doi.org/10.1177/14791641221130043
Background The indication for treatment of type 1 diabetes(T1D) with the sodium–glucose cotransporter 2 inhibitor (SGLT2i) dapagliflozin has been withdrawn in Europe likely because of concern for diabetic ketoacidosis (DKA). We calculated the incid